Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.

Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, Linder M, Bode B

Diabetes care9 Aug 2016Cited by 270 (Europe PMC)

PMID27506222DOI10.2337/dc16-0691PepBankPUB-27506222

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 1.8 mg lowered HbA1c more than placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c treatment difference
−0.2%
liraglutide 1.8 mg
Source sentences
Summary
HbA1c level was reduced 0.34-0.54% (3.7-5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide -0.20% [95% CI -0.32; -0.07]; 1.2 mg liraglutide -0.15% [95% CI -0…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622201
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 1.2 mg lowered HbA1c more than placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c treatment difference
−0.15%
liraglutide 1.2 mg
Source sentences
Summary
HbA1c level was reduced 0.34-0.54% (3.7-5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide -0.20% [95% CI -0.32; -0.07]; 1.2 mg liraglutide -0.15% [95% CI -0…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622202
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 0.6 mg did not lower HbA1c significantly more than placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg did not lower HbA1c significantly more than placebo.
Peptide
Liraglutide
Outcome
No significant changeHbA1c treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c treatment difference
−0.09%
liraglutide 0.6 mg
Source sentences
Summary
HbA1c level was reduced 0.34-0.54% (3.7-5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide -0.20% [95% CI -0.32; -0.07]; 1.2 mg liraglutide -0.15% [95% CI -0…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622203
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, adding liraglutide 1.8 mg reduced the insulin dose versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg lowered the insulin dose needed compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose (treatment ratio vs placebo)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated treatment ratio
0.92 ratio
liraglutide 1.8 mg
Source sentences
Summary
Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622204
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, adding liraglutide 1.2 mg reduced the insulin dose versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg lowered the insulin dose needed compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose (treatment ratio vs placebo)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated treatment ratio
0.95 ratio
liraglutide 1.2 mg
Source sentences
Summary
Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622205
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, adding liraglutide 0.6 mg did not change the insulin dose versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg did not change the insulin dose needed compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeInsulin dose (treatment ratio vs placebo)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated treatment ratio
1 ratio
liraglutide 0.6 mg
Source sentences
Summary
Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622206
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 1.8 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.8 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Body weight treatment difference
−4.9 kg
liraglutide 1.8 mg
Source sentences
Summary
Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide -4.9 kg [95% CI -5.7; -4.2]; 1.2 mg liraglutide -3.6 kg [95% CI -4.3; -2.8]; 0.6 mg liraglutide -2.2 kg [95% CI -2.9; -1.5]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622207
08HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 1.2 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 1.2 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Body weight treatment difference
−3.6 kg
liraglutide 1.2 mg
Source sentences
Summary
Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide -4.9 kg [95% CI -5.7; -4.2]; 1.2 mg liraglutide -3.6 kg [95% CI -4.3; -2.8]; 0.6 mg liraglutide -2.2 kg [95% CI -2.9; -1.5]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622208
09HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes on insulin, liraglutide 0.6 mg reduced body weight versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide 0.6 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight treatment difference vs placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Body weight treatment difference
−2.2 kg
liraglutide 0.6 mg
Source sentences
Summary
Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide -4.9 kg [95% CI -5.7; -4.2]; 1.2 mg liraglutide -3.6 kg [95% CI -4.3; -2.8]; 0.6 mg liraglutide -2.2 kg [95% CI -2.9; -1.5]).
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622209
10HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on insulin, symptomatic hypoglycemia was more frequent with liraglutide 1.8 mg than with placebo.
In plain wordsIn adults with type 1 diabetes, low blood sugar with symptoms was more common with liraglutide 1.8 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseSymptomatic hypoglycemia rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated rate ratio
1.31 ratio
liraglutide 1.8 mg
Source sentences
Summary
The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglut…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622210
11HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on insulin, symptomatic hypoglycemia was more frequent with liraglutide 1.2 mg than with placebo.
In plain wordsIn adults with type 1 diabetes, low blood sugar with symptoms was more common with liraglutide 1.2 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseSymptomatic hypoglycemia rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated rate ratio
1.27 ratio
liraglutide 1.2 mg
Source sentences
Summary
The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglut…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622211
12HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on insulin, the symptomatic hypoglycemia rate with liraglutide 0.6 mg was not significantly different from placebo.
In plain wordsIn adults with type 1 diabetes, low blood sugar with symptoms was not clearly more common with liraglutide 0.6 mg than with placebo.
Peptide
Liraglutide
Outcome
No significant changeSymptomatic hypoglycemia rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Estimated rate ratio
1.17 ratio
liraglutide 0.6 mg
Source sentences
Summary
The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglut…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622212
13HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on insulin, hyperglycemia with ketosis was more frequent with liraglutide 1.8 mg than with placebo.
In plain wordsIn adults with type 1 diabetes, high blood sugar with ketones was more common with liraglutide 1.8 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseHyperglycemia with ketosis rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Event rate ratio
2.22 ratio
liraglutide 1.8 mg
Source sentences
Summary
The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglut…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622213
14HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes on insulin, hyperglycemia with ketosis did not increase significantly with liraglutide 1.2 or 0.6 mg; only the 1.8 mg dose increased it.
In plain wordsIn adults with type 1 diabetes, high blood sugar with ketones did not clearly increase with the lower liraglutide doses.
Peptide
Liraglutide
Outcome
No significant changeHyperglycemia with ketosis rate
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 and 0.6 mg once daily · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglut…
1 context sentence(design, population, supporting numbers)
Summary · context
A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin.
Report a problemFND-2750622214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 3NCT06894784

A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes

McGill University Health Centre/Research Institute of the McGill University Health Centren = 36est. Apr 2025 to est. Jan 2027

Diabetes Type 1

Trial page ClinicalTrials.govUpdated 30 Mar 2025

RecruitingPhase 2NCT05478707

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

AdventHealth Translational Research Instituten = 475 Oct 2023 to est. 30 Jul 2028

Diabetes Mellitus, Type 1 · Endothelial Dysfunction

Trial page ClinicalTrials.govUpdated 15 Oct 2026

CompletedPhase 3Results postedNCT01836523

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Novo Nordisk A/Sn = 1,398Nov 2013 to Jun 2015

Diabetes · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 6 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.